TransCode Therapeutics Inc. (RNAZ): Growth-Adjusted Market Cap to Net Income

TransCode Therapeutics (RNAZ) brings together top geneticists to develop RNA-based cancer drugs. The undervalued growth company screener visualizes the asset's value dynamics, where 0.00 shows the current metric volume. High profitability is driven by steady clinic demand for innovative molecules, although final capitalization depends on the clinical test results of nanoparticles for metastasis therapy.

This metric compares the current P/E multiple with the net income growth rate to determine the fairness of the asset's market value relative to its dynamics. A value below one signals undervaluation, which is critically important for TransCode Therapeutics (RNAZ) during the scaling of its RNA drug delivery platform, allowing the PEG ratio to assess the investment efficiency of its expansion into the oncology market.